# Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment

> **NCT05661461** · PHASE1 · RECRUITING · sponsor: **Aadi Bioscience, Inc.** · enrollment: 28 (estimated)

## Conditions studied

- Tumor, Solid
- Tumor
- Advanced Solid Tumor

## Interventions

- **DRUG:** nab-sirolimus

## Key facts

- **NCT ID:** NCT05661461
- **Lead sponsor:** Aadi Bioscience, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-23
- **Primary completion:** 2026-06-01
- **Final completion:** 2026-08-01
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2025-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05661461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05661461, "Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05661461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*